Nasdaq:RPID
RAPID MICRO BIOSYSTEMS, INC.
A microfluidics developer leveraging proprietary chip technology to accelerate drug discovery and enable portable diagnostic solutions for clinical settings.
Key Metrics
Investment Thesis
Bull Case
The consistent year-over-year revenue growth from $17.1M to $28.1M demonstrates strong product-market fit and expanding commercial traction in the microfluidics sector. With a healthy current asset base of $80.9M against only $17.6M in current liabilities, the company maintains sufficient liquidity to fund its research pipeline and weather market volatility.
Bear Case
The deepening losses and negative cash flow from operations suggest the business model has not yet achieved commercial scalability or profitability without significant external funding. The large retained earnings deficit of -$475.3M and negative operating profit of -$49.9M highlight substantial ongoing burn that may deter conservative investors.
About RAPID MICRO BIOSYSTEMS, INC.
RAPID MICRO BIOSYSTEMS, INC. is a biotechnology firm focused on developing next-generation microfluidic platforms and diagnostic systems for clinical research and point-of-care testing. The company serves markets including oncology, infectious disease, and genetic screening through its proprietary rapid analysis technologies. Key revenue streams derive from the sale of specialized instrumentation, reagent kits, and licensing agreements with academic and commercial partners.
Analysis
Management Discussion
While revenue grew 60% over three years to $28.1M, operating expenses surged to $78.0M driven by aggressive R&D and marketing spend of $13.3M. The company recorded a net loss of -$46.9M in 2024 with cash from operations at -$44.2M, yet it managed to increase its cash position via financing inflows despite heavy investing outflows for securities.
Industry Overview
The microfluidics and point-of-care diagnostics industry is experiencing rapid expansion as healthcare providers seek faster, portable testing solutions for infectious diseases and cancer biomarkers. Companies in this space face high barriers to entry due to complex chip fabrication requirements but offer significant upside potential once regulatory approvals are secured.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $17.1M | $22.5M | $28.1M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $17.1M | $22.5M | $28.1M |
| Operating Expenses | $80.4M | $79.1M | $78.0M |
| Operating Income | $-63.2M | $-56.6M | $-49.9M |
| R&D | $12.9M | $12.8M | $14.6M |
| G&A | $26.8M | $24.9M | $21.9M |
| Marketing | $15.0M | $13.3M | $13.3M |
| Stock-Based Comp | $4.0M | $4.8M | $3.9M |
| D&A | $2.8M | $3.1M | $3.4M |
| Other OpEx | $25.7M | $28.0M | $28.2M |
| Non-Operating Income | $1.8M | $4.1M | $3.1M |
| Pre-Tax Income | $-61.4M | $-52.4M | $-46.9M |
| Income Tax | $-576.0K | $31.0K | $22.0K |
| Continuing Ops | $-60.8M | $-52.5M | $-46.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-60.8M | $-52.5M | $-46.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-60.8M | $-52.5M | $-46.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $138.6M | $120.4M | $80.9M |
| Cash & Equivalents | $27.1M | $24.3M | $16.9M |
| Accounts Receivable | $5.4M | $5.5M | $7.5M |
| Inventory | $21.2M | $20.0M | $20.2M |
| Prepaid Expenses | $3.4M | $2.9M | $2.5M |
| Other Current Assets | $81.6M | $67.8M | $33.8M |
| Long-Term Assets | $52.1M | $23.0M | $17.3M |
| PP&E (Net) | $13.8M | $12.8M | $11.2M |
| Operating Leases | $6.7M | $6.0M | $5.0M |
| Other LT Assets | $31.5M | $4.2M | $1.1M |
| Total Assets | $190.7M | $143.5M | $98.2M |
| Current Liabilities | $19.1M | $19.0M | $17.6M |
| Accounts Payable | $5.4M | $2.0M | $2.5M |
| Current Leases | $729.0K | $1.1M | $1.2M |
| Deferred Revenue | $4.7M | $6.0M | $6.6M |
| Taxes Payable | $329.0K | $252.0K | $235.0K |
| Other Current Liab | $-292.0K | $-210.0K | $-188.0K |
| Long-Term Liabilities | $7.4M | $6.5M | $5.3M |
| LT Operating Leases | $6.9M | $6.0M | $4.8M |
| Other LT Liab | $533.0K | $525.0K | $468.0K |
| Total Liabilities | $26.5M | $25.5M | $22.8M |
| Shareholders' Equity | $164.2M | $118.0M | $75.4M |
| Paid-In Capital | $540.8M | $546.1M | $550.2M |
| Retained Earnings | $-375.9M | $-428.4M | $-475.3M |
| AOCI | $-1.1M | $-101.0K | $39.0K |
| Total L&E | $190.7M | $143.5M | $98.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-60.8M | $-52.5M | $-46.9M |
| Non-Cash Adjustments | $-3.3M | $9.4M | $3.4M |
| Working Capital Changes | $5.6M | $-2.1M | $-633.0K |
| Cash from Operations | $-58.5M | $-45.1M | $-44.2M |
| Capital Expenditures | $6.7M | $1.8M | $1.4M |
| Cash from Investing | $-93.5M | $42.2M | $36.7M |
| Debt Repayments | $0 | — | — |
| Cash from Financing | $693.0K | $149.0K | $203.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-151.3M | $-2.8M | $-7.3M |
| Beginning Cash | $178.7M | $27.3M | $24.6M |
| Ending Cash | $27.3M | $24.6M | $17.3M |
Frequently Asked Questions
How does RAPID MICRO BIOSYSTEMS, INC. make money?
Instrumentation sales generating gross profit from high-margin hardware platforms; Reagent and consumable kits providing recurring revenue tied to instrument usage; Licensing and collaboration fees derived from intellectual property partnerships with pharmaceutical and academic entities.
What are the main risks for RPID?
Persistent net losses and a substantial retained earnings deficit of -$475.3M indicate high burn rates and potential capital constraints; Heavy reliance on non-operating income ($3.1M) suggests core operations are not yet self-sustaining; Significant investment in marketable securities ($35.0M purchases) exposes the balance sheet to interest rate fluctuations if funds are locked long-term.
What is RPID's competitive advantage?
Proprietary microfluidic chip architecture enabling faster sample-to-answer times compared to traditional PCR methods; Strong pipeline of R&D investments ($14.6M in 2024) targeting differentiated assays for rare disease detection; Scalable manufacturing capabilities supported by significant cash flow from financing activities.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.